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The Editorial Board of this JOURNAL has established the policy that where there is an 
interesting and sharp difference of opinion between an author and a reviewer, if it appeared 
to be more valuable to publish a statement of the differences than to attempt to make one 
of the disputants agree with the other, this would be done with the permission of both 
parties. In this way interesting as well as educational material which would otherwise be 
lost is published. The publication of a reviewer's commentary should make his contribution 
a more substantial one, to the reader as well as to the author. It is for this reason that we 
publish a commentary on Dr. Berger's paper and leave it to the reader to come to his own 
conclusions. Editor. 
Commentary on preceding article 
The author should be congratulated for bring-
ing together a large number of pertinent and di-
versified references dealing with his chosen sub-
ject. There is no question in my mind that 
meprobamate differs in some respects from barbi-
turates. One can compare chemical structures, 
physical and chemical properties, and finally 
pharmacologic actions and show many differences 
as well as similarities. The same sort of statement, 
however, can be made for pentobarbital versus 
phenobarbital. Depending upon one's objective, 
the differences or the similarities can be empha-
sized. 
My principal objection to the manuscript is that 
the title would suggest that the similarities as well 
as the differences between meprobamate and bar-
biturates will be discussed equally. The manu-
script clearly is biased toward the differences, 
frequently being noncritical of the reputed dif-
ferences, and very critical of the similarities. As 
a result, the manuscript provides excellent copy 
for drug advertisements but little scientific objec-
tivity. As discoverer of meprobamate, the author 
is so close to it that it is difficult, if not impos-
sible, for him to be completely objective in dis-
cussing his highly successful "offspring." 
The following are specific pOints which I would 
like to comment on. 
Page 209, paragraph 2. The author refers to 
his own publications classifying meprobamate as 
a "central relaxant." Surely, he has had personal 
experience with cocktails and can attest to the 
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fact that ethyl alcohol in proper dose would fit 
his definition of a "central relaxant." In fact, the 
author should have discussed meprobamate in 
relation to ethyl alcohol as well. 
Page 209, paragraph 3. After creating a new 
classification for meprobamate to differentiate it 
from the phenothiazines, the author refers to the 
barbiturates as sedative hypnotics which of course 
they are. However, they can also be used as "cen-
tral relaxants." I would disagree with the state-
ment, "Barbiturates resemble one another very 
closely .... " Phenobarbital has a selective motor 
depressant effect that clearly is not present with 
pentobarbital, etc. Amobarbital has a euphor-
ogenic effect not present with barbital, etc. 
It is, therefore, not correct to say that the dif-
ferences between barbiturates are quantitative. 
He should not use the word barbiturates so in-
discriminately but refer to specific ones more fre-
quently. 
Page 210, column 1, lines 6-10. The author 
implies that "barbiturates" and meprobamate have 
a single site of action which is different. These 
agents have many sites of action. Frequently the 
two classes of drugs have similar sites of action 
(for example, depression of the hippocampus) but 
differ quantitatively. They have similar clinical 
applications in many situations. 
Page 210, column 1, lines 20-29. The author 
should specify in detail the effects of a large 
variety of barbiturates for there are appreciable 
differences in the amount of excitation with each. 
The statement, "After meprobamate, animals 
rested peacefully .... " could apply to pheno-
barbital in proper dose. 
Page 210, column 1, lines 36-43. The state-
ment that the reticular activating system is the 
site of action of sedative hypnotics refers to a 
relatively old article which does not give all of 
the presently known facts. It is therefore entirely 
inadequate and inappropriate. For example, there 
is good evidence that very low doses of barbi-
turates depress the hypothalamus, cortex, and 
limbic system. 
Page 210, section "effects on the reticular ac-
tivity system." This section is markedly oversimpli-
fied, especially in the light of research in the past 
few years. The activating system includes medul-
lary as well as hypothalamic components in addi-
tion to the midbrain. The diffuse thalamic projec-
tion system is more involved with sleep than 
arousal, especially when recruiting responses are 
elicited. The statement "so-called arousal" for low 
voltage, fast frequency activity is not as critical as 
it should be inasmuch as the same activity is seen 
during dreaming and low doses of meprobamate 
and certain barbiturates. The reference to Magoun 
that sedatives block this response in nonhypnotic 
doses lacks the qualification of level of stimulation 
with regard to threshold. 
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Page 210. Table I serves no useful purpose in 
its present form for the 1:4 ratio of pentobarbital 
and meprobamate assumes parallel slopes of the 
dose-response curves. The author might argue that 
human doses are also in a 1:4 ratio. However, in 
all probability meprobamate has a much shallower 
dose response curve. Therefore, much larger doses 
of meprobamate or smaller doses of pentobarbital 
should have been used for the comparison. This is 
critical with respect to much of the research in 
animals that the author subsequently reviews. 
Page 211, first column. The author should try 
to explain the discrepancies between the data of 
Gangloff (more stimulation of reticular formation) 
and Takaori and Ohato (no effect or depression of 
reticular formation) or conclude that Gangloff's 
findings were not confirmed. In fact Gangloff con-
fuses the issue by not differentiating fast waves of 
activation from fast waves of depression as in the 
case of barbiturate or meprobamate fast waves. 
The author makes a strong point of the differences 
between meprobamate and barbiturates as per 
Gangloff, and does not equally emphasize the 
similarities of barbiturates and meprobamate as 
per Takaori and Ohato. 
Page 211, paragraph beginning "The effect of 
meprobamate." This summary paragraph should 
point out that all of the previous studies referred 
to did not include thorough dose-response curve 
data and that many of the reported differences 
between some barbiturates and meprobamate may 
be related to this. 
Page 212, column 2, paragraph 1. In criticizing 
the research of Shagass and co-workers, the author 
fails to appreciate the importance of tolerance de-
velopment to meprobamate. This is why the dose 
can be increased to such large levels and still be 
relatively ineffectual clinically. 
Page 214, column 1, paragraph 2. The author 
should emphasize more the work of Abdulian and 
co-workers pointing out the similarities of mepro-
bamate to pentobarbital rather than to mephenesin 
and SKF 1045. The author fails to refer to the 
work of King and others that small doses of pento-
barbital block the polysynaptic reflexes selectively 
just like mephenesin. Important articles such as 
that of Pfeiffer and associates are referred to pri-
marily in order to emphasize the differences rather 
than the similarities of meprobamate to other seda-
tives. 
Page 217, Table II. Should it not refer to only 
those differences that are statistically significant? 
Why are comparisons of parameters in which the 
differences are not statistically significant included? 
The table in its present form gives the impression 
of far more differences than are statistically veri-
fied. Dose relationships should include even 
smaller doses of secobarbital. 
Page 218, column 1, paragraph 2, line 11, 
sentence, "This is not surprising as the drug was 
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given at four times .... " The point is that large 
doses can depress these functions like any other 
sedative in large doses. Therefore, in this re:;pect 
meprobamate does resemble a sedative. 
Page 218, column I, paragraph 3. The impor-
tant pOint of quantitative rather than qualitative 
differences to other sedatives is not stressed. 
Page 218, column 2, paragraph 1. The author 
gives the wrong impression of the work of Pfeiffer 
and associates on conditioned reflexes. Mep-
robamate does not have a selective effect on 
avoidance behavior, just like a barbiturate. He 
fails to quote Hertz as well as other workers on 
this pOint. 
Page 219, column 2, paragraph 1. The research 
of Hughes and co-workers should have been criti-
cized on the basis of the doses of the various 
drugs used. Therefore, their trancpIilizer indexes 
are meaningless. 
Page 220, column I, paragraph 1. The first 
sentence is quite objectionable because it implies 
barbiturates are ineffective in psychoneurotics. The 
real pOint is that meprobamate eame at a time 
when physicians were overly concerned with the 
hazards of addiction to barbiturates and were 
ready for something described by a catch phrase 
as a so-called "nonaddicting tranquilizing muscle 
relaxant without autonomic nervous systems ef-
fects," etc. 
Page 224, first paragraph. The "infrequent" use 
of meprobamate may be related to the less fre-
quent therapeutic lise of meprobamate than barbi-
turates. 
Page 224, last half of first column. The discus-
sion should be modified in accordance with some 
of the above comments. 
Page 224, second half of second column 
through first column of page 225. The criticisms 
of Laties and \Veiss conclusions should include 
the concept of dose. This can apply to both mep-
robamate, amobarbital, and other barbiturates. 
Page 225, column I, last two lines, to end of 
paragraph. I would criticize the "well-planned" 
experiments of Rickels and associates and Dickel 
and co-workers in that an inadequate sample size, 
range of dosage, and variety of barbiturates were 
used. 
Page 225, last 16 lines. There is nothing about 
the study of Uhlenhuth and associates that offends 
common sense. It simply indicates that the doc-
tor-patient relationship can be more important 
than the pill given. One cannot throw out data 
because it offends one person's common sense. 
Small "therapeutic" doses of these agents were 
apparently insufficient to demonstrate a real phar-
macologic effect in certain doctor-patient situa-
tions. 
Page 226, paragraph 1. The statements are 
not based upon adequate evidence. Table III is 
inadequate in that it does not provide the con-
cept of dose used. Furthermore, it is in disagree-
ment with the data of other investigators whom 
the author fails to quote but is aware of from 
his reference list. 
Page 226, paragraph 1, line 17. This sentence 
simply is not true! Deep anesthesia cannot be 
produced by small doses of chlorpromazine in 
animals. 
Page 226, column I, line 6 from bottom. The 
author fails to refer to all references in the liter-
ature when he makes a conclusion. Motor impair-
ment has been described by many others. The 
author is so preoccupied with the 400 mg. dose 
of meprobamate that he fails to recognize that 
many of the effects which are lacking with the 
use of meprobamate are quantitative and not 
qualitative. 
Page 226, column 2, paragraph 1. The term 
"nonspecific" depression is meaningless. At our 
present state of knowledge no one can decide 
what is "specific" and "nonspecific" depression of 
the central nervous system. 
Page 227, concluding paragraph. This sum-
mary paragraph suggests bias by the author. For 
example, barbiturates are primarily useful as seda-
tive-hypnotics. Tme! But So is meprobamate! The 
author fails to draw such a conclusion in spite of 
ample evidence. There is no universal agreement 
that meprobamate specifically relieves anxiety. 
How then can the author make such a conclu-
sion? 
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